Ayala Pharmaceuticals Inc
NASDAQ:AYLA
Income Statement
Earnings Waterfall
Ayala Pharmaceuticals Inc
Revenue
|
1.7m
USD
|
Cost of Revenue
|
-1.6m
USD
|
Gross Profit
|
90k
USD
|
Operating Expenses
|
-37.6m
USD
|
Operating Income
|
-37.5m
USD
|
Other Expenses
|
-932k
USD
|
Net Income
|
-38.5m
USD
|
Income Statement
Ayala Pharmaceuticals Inc
Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | ||
---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue |
3
N/A
|
4
+37%
|
4
-1%
|
3
-8%
|
3
-1%
|
4
+4%
|
3
-15%
|
2
-24%
|
2
-24%
|
|
Gross Profit | ||||||||||
Cost of Revenue |
(3)
|
(4)
|
(4)
|
(3)
|
(3)
|
(4)
|
(3)
|
(2)
|
(2)
|
|
Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
Operating Income | ||||||||||
Operating Expenses |
(20)
|
(30)
|
(33)
|
(37)
|
(39)
|
(39)
|
(40)
|
(37)
|
(38)
|
|
Selling, General & Administrative |
(5)
|
(7)
|
(8)
|
(9)
|
(10)
|
(9)
|
(9)
|
(9)
|
(10)
|
|
Research & Development |
(16)
|
(22)
|
(24)
|
(27)
|
(29)
|
(30)
|
(31)
|
(28)
|
(28)
|
|
Operating Income |
(20)
N/A
|
(30)
-46%
|
(33)
-9%
|
(37)
-12%
|
(39)
-6%
|
(39)
-1%
|
(40)
-2%
|
(37)
+7%
|
(38)
-1%
|
|
Pre-Tax Income | ||||||||||
Interest Income Expense |
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Pre-Tax Income |
(20)
N/A
|
(30)
-46%
|
(33)
-10%
|
(37)
-13%
|
(39)
-6%
|
(39)
-1%
|
(40)
-1%
|
(37)
+7%
|
(38)
-1%
|
|
Net Income | ||||||||||
Tax Provision |
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
|
Income from Continuing Operations |
(21)
|
(30)
|
(33)
|
(37)
|
(40)
|
(40)
|
(41)
|
(38)
|
(38)
|
|
Net Income (Common) |
(21)
N/A
|
(30)
-45%
|
(33)
-10%
|
(37)
-12%
|
(40)
-6%
|
(40)
-2%
|
(41)
-1%
|
(38)
+6%
|
(38)
-1%
|
|
EPS (Diluted) |
-1.64
N/A
|
-2.36
-44%
|
-2.57
-9%
|
-2.58
0%
|
-2.73
-6%
|
-2.65
+3%
|
-2.66
0%
|
-2.49
+6%
|
-2.48
+0%
|